PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis
Inc. (NYSE:ZTS) today announced the results of shareholder voting at
its 2019 Annual Meeting of Shareholders and provided details on its
third quarter 2019 dividend.
Annual Meeting of Shareholders
Zoetis held its annual meeting today in Short Hills, N.J., with Chairman
Michael B. McCallister presiding over the business portion of the
meeting and shareholder voting. Chief Executive Officer Juan Ramón Alaix
discussed the company’s strong performance in 2018 and its strategies
for continued growth and market leadership in the global animal health
industry.
The results of shareholder voting from the meeting were as follows:
-
Juan Ramón Alaix, Paul M. Bisaro, Frank A. D’Amelio and Michael B.
McCallister have been elected as directors for three-year terms.
-
Shareholders approved, on an advisory basis, the compensation of the
company’s named executive officers.
-
Shareholders ratified and approved the selection of KPMG LLP as the
company’s independent registered public accounting firm for fiscal
year 2019.
As part of his remarks about the company, Alaix said, “In 2018, we
delivered our sixth consecutive year of operational revenue growth and
increased profitability. We also made further investments in our
business, both through research and development, as well as acquisitions
and external partnerships. As we look to the future, I am confident that
we will continue to grow in line with or faster than the market, based
on the strength of our diverse and innovative portfolio, high-quality
manufacturing, and world-class field-force.”
A full replay of the meeting will be made available at http://investor.zoetis.com/events-presentations,
along with the presentation materials from the event.
Quarterly Dividend Declared
In separate proceedings today, the Zoetis Board of Directors declared a
third quarter 2019 dividend payable to holders of the company’s common
stock of $0.164 per share; the dividend is to be paid on Tuesday, Sept.
3, 2019, to holders of record on Friday, July 19, 2019.
About Zoetis
Zoetis
is the leading animal health company, dedicated to supporting its
customers and their businesses. Building on more than 65 years of
experience in animal health, Zoetis discovers, develops, manufactures
and commercializes veterinary vaccines, medicines and diagnostics, which
are complemented by genetic tests, biodevices and a range of services.
Zoetis serves veterinarians, livestock producers and people who raise
and care for farm and companion animals with sales of its products in
more than 100 countries. In 2018, the company generated annual revenue
of $5.8 billion with approximately 10,000 employees. For more
information, visit
www.zoetis.com
.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains
forward-looking statements, which reflect the current views of Zoetis
with respect to business plans or prospects, future operating or
financial performance, future use of cash and dividend payments, and
other future events. These statements are not guarantees of future
performance or actions. Forward-looking statements are subject to risks
and uncertainties. If one or more of these risks or uncertainties
materialize, or if management's underlying assumptions prove to be
incorrect, actual results may differ materially from those contemplated
by a forward-looking statement. Forward-looking statements speak only as
of the date on which they are made. Zoetis expressly disclaims any
obligation to update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise. A further list
and description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended December 31,
2018, including in the sections thereof captioned “Forward-Looking
Statements and Factors That May Affect Future Results” and “Item 1A.
Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current
Reports on Form 8-K. These filings and subsequent filings are available
online at
www.sec.gov
,
www.zoetis.com
,
or on request from Zoetis.
Media:
Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com
Investors:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com